Pharma / Biotech

FDA Advisory Panel Considers Descovy for PrEP

In a 16-to-2 vote, the FDA Antimicrobial Drugs Advisory Committee (AMDAC) recommended approval of a new indication for emtricitabine–tenofovir alafenamide (F/TAF; Descovy, Gilead) for pre-exposure prophylaxis (PrEP) to reduce the risk for HIV in some, but not all, at-risk populations.

Source link

Related posts

clinical pharmacology; +200 new citations


journal pharmacology; +720 new citations


POLMON (Dexchlorpheniramine Maleate) Solution [Capellon Pharmaceuticals, LLC]


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy